Akili Interactive, the company behind a video game-like prescription digital therapeutic for children with ADHD, reported its first full-year earnings since going public last year.
The company reported $323,000 in revenue for 2022 compared with $538,000 for 2021. Akili said 2022 revenue was entirely made up of funds earned from sales of EndeavorRx, its therapeutic that received FDA clearance for...
Video-game therapy. Digital therapeutic maker Akili announced that its video-game-like therapy for children with ADHD, dubbed EndeavorRx, will now be available on Android devices. The prescription digital therapeutic is geared towards kids 8 to 12 who are diagnosed with ADHD.
The company scored an FDA De Novo for the product in 2020, making it the first game-based therapeutic with clearance. In...
EndeavorRx, the FDA De Novo-authorized video game digital therapeutic for children with ADHD, is getting a slew of new gameplay features, its developer Akili Interactive announced today.
EndeavorRx takes the form of a game in which users navigate an alien avatar through a course while they respond to on-screen prompts. The app keeps track of movements, monitors the user’s behavior and quickly...
Akili Interactive, the maker of the FDA De Novo-authorized digital therapeutic EndeavorRx, will be testing its video game ADHD treatment as a potential treatment for cognitive impairments in COVID-19 survivors.
Through collaborations with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center, Akili will conduct two separate randomized, controlled clinical...
Akili Interactive has published the full data from its STARS-ADHD Adjunctive trial. The data builds upon the company's pivotal study of AKL-T01 (now available as EndeavorRx) and suggests the videogame-like digital therapeutic delivers benefits with or without accompanying stimulant medication, and that they persist up to one month following the treatment.
"These results increase the...
After years of waiting, Akili Interactive has finally received FDA De Novo marketing authorization for EndeavorRx, its video-game digital therapeutic for children aged 8 to 12 years with ADHD.
This is the first game-based therapeutic that the FDA has greenlit for any condition, the regulatory agency noted in its announcement. It is also the first authorization for Akili, which has a handful of...
